• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高级别乳头状甲状腺癌,弥漫硬化亚型:18例病例系列,详述病理特征、误诊可能性及侵袭性临床行为

High-Grade Papillary Thyroid Carcinoma, Diffuse Sclerosing Subtype: A Series of 18 Cases Detailing the Pathologic Features, Potential for Misdiagnosis, and Aggressive Clinical Behavior.

作者信息

Ghossein Ronald A, Scholfield Daniel W, Qin Howard, Shaha Ashok R, Ganly Ian, Xu Bin

机构信息

Department of Pathology and Laboratory Medicine.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Am J Surg Pathol. 2025 May 1;49(5):481-489. doi: 10.1097/PAS.0000000000002371. Epub 2025 Mar 27.

DOI:10.1097/PAS.0000000000002371
PMID:40143646
Abstract

High-grade differentiated thyroid carcinoma is a novel classification defined by elevated mitotic count (MC) of ≥5/2 mm 2 and/or tumor necrosis. It may assume a phenotype of papillary thyroid carcinoma, diffuse sclerosing subtype (PTC-DS), and can be termed HGPTC-DS. A detailed clinicopathologic review was conducted on a large series of 18 cases of HGPTC-DS. A control group of 41 PTC-DSs with genomic data was also included. Histologically, HGPTC-DS showed typical features of PTC-DS and HG areas, often exhibiting solid architecture of uniform squamoid cells admixed with tumor necrosis, frequently the comedo type. All HGDTC-DSs had tumor necrosis. The MC was often low (median 1/2 mm 2 ). PTC nuclear features were retained and no nuclear pleomorphism was seen. HGPTC-DS was often subjected to misdiagnosis. Among the 7 external cases, the initial diagnosis was anaplastic carcinoma in 1 and PTC in 5. Compared with PTC-DS, HGPTC-DS was associated with positive resection margin, AJCC eighth edition pT3b and pT4a/4b disease, gross extrathyroidal extension (ETE), a higher number of regional lymph nodes metastasis, a larger size of nodal metastasis, decreased recurrence-free survival (RFS) and regional recurrence-free survival ( P <0.05). Among the 9 HGPTC-DSs sequenced, 5 harbored RET fusions, 2 had STRN::ALK fusion, and 1 had BRAF p.V600E mutation. In conclusion, HGPTC-DS is a rare high-grade carcinoma characterized by uniform squamoid area with comedo-type tumor necrosis, high pT stage, gross ETE, large volume nodal metastasis, poor RFS, and RRFS. Given its rarity, it may be subjected to misdiagnosis as PTC and anaplastic carcinoma.

摘要

高级别分化型甲状腺癌是一种新的分类,定义为有丝分裂计数(MC)≥5/2mm²升高和/或肿瘤坏死。它可能呈现甲状腺乳头状癌弥漫硬化亚型(PTC-DS)的表型,可称为HGPTC-DS。对18例HGPTC-DS的大样本进行了详细的临床病理回顾。还纳入了一个有基因组数据的41例PTC-DS对照组。组织学上,HGPTC-DS显示PTC-DS和高级别区域的典型特征,常表现为均匀鳞状细胞的实性结构并伴有肿瘤坏死,常见粉刺型。所有HGDTC-DS均有肿瘤坏死。MC通常较低(中位数为1/2mm²)。保留了PTC的核特征,未见核异型性。HGPTC-DS常被误诊。在7例外部病例中,最初诊断为间变性癌1例,PTC 5例。与PTC-DS相比,HGPTC-DS与手术切缘阳性、美国癌症联合委员会(AJCC)第八版pT3b和pT4a/4b期疾病、肉眼可见的甲状腺外侵犯(ETE)、区域淋巴结转移数量较多、淋巴结转移灶较大、无复发生存期(RFS)和区域无复发生存期降低相关(P<0.05)。在9例测序的HGPTC-DS中,5例存在RET融合,2例有STRN::ALK融合,1例有BRAF p.V600E突变。总之,HGPTC-DS是一种罕见的高级别癌,其特征为均匀的鳞状区域伴粉刺型肿瘤坏死、高pT分期、肉眼可见的ETE、大量淋巴结转移、RFS和RRFS较差。鉴于其罕见性,它可能被误诊为PTC和间变性癌。

相似文献

1
High-Grade Papillary Thyroid Carcinoma, Diffuse Sclerosing Subtype: A Series of 18 Cases Detailing the Pathologic Features, Potential for Misdiagnosis, and Aggressive Clinical Behavior.高级别乳头状甲状腺癌,弥漫硬化亚型:18例病例系列,详述病理特征、误诊可能性及侵袭性临床行为
Am J Surg Pathol. 2025 May 1;49(5):481-489. doi: 10.1097/PAS.0000000000002371. Epub 2025 Mar 27.
2
Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.具有显著鞋钉样特征的甲状腺乳头状癌的细胞学、临床病理及分子特征:10例病例报告及系统文献综述
Int J Clin Exp Pathol. 2015 Jul 1;8(7):7988-97. eCollection 2015.
3
Association Between Gross Features and Coexistence of and Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features.甲状腺乳头状癌大体特征与BRAF和TERT启动子突变共存之间的关联:结合临床病理特征的综合分析
Thyroid. 2024 Dec;34(12):1476-1485. doi: 10.1089/thy.2024.0310. Epub 2024 Oct 31.
4
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.甲状腺乳头状癌中的BRAF突变及其在制定初始治疗方案中的价值:一项系统评价和荟萃分析。
Medicine (Baltimore). 2012 Sep;91(5):274-286. doi: 10.1097/MD.0b013e31826a9c71.
5
Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.BRAF V600E等位基因频率与甲状腺乳头状癌临床病理结果的相关性
J Clin Endocrinol Metab. 2024 Nov 14. doi: 10.1210/clinem/dgae774.
6
RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.在乳头状甲状腺癌中,RET融合而非BRAF突变会带来更高的侵袭性和复发风险。
Oral Oncol. 2025 Aug;167:107464. doi: 10.1016/j.oraloncology.2025.107464. Epub 2025 Jul 3.
7
MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review.甲状腺乳头状癌中微小RNA的表达及其与临床病理特征的关联:一项系统评价
Thyroid. 2015 Dec;25(12):1322-9. doi: 10.1089/thy.2015.0193. Epub 2015 Oct 8.
8
The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant : A Systematic Review and Meta-Analysis.淋巴细胞性甲状腺炎与携带突变的甲状腺乳头状癌之间的关联:一项系统评价和荟萃分析。
Thyroid. 2024 Sep;34(9):1082-1093. doi: 10.1089/thy.2024.0142. Epub 2024 Jul 18.
9
Comparative analysis of follicular cell- derived thyroid carcinoma: assessing the impact of high-grade features in an advanced disease cohort.滤泡细胞源性甲状腺癌的比较分析:评估高级别特征在晚期疾病队列中的影响。
Virchows Arch. 2025 May 2. doi: 10.1007/s00428-025-04109-2.
10
Risk and Prognostic Factors for BRAF Mutations in Papillary Thyroid Carcinoma.甲状腺乳头状癌中 BRAF 突变的风险和预后因素。
Biomed Res Int. 2022 May 18;2022:9959649. doi: 10.1155/2022/9959649. eCollection 2022.

引用本文的文献

1
Expanding the histologic spectrum of thyroid neoplasms with NTRK1/2/3 or ALK translocation: a single-center retrospective study of 82 cases.扩展伴有NTRK1/2/3或ALK易位的甲状腺肿瘤的组织学谱:一项82例单中心回顾性研究
Virchows Arch. 2025 May 30. doi: 10.1007/s00428-025-04133-2.

本文引用的文献

1
Defining angioinvasion and lymphatic invasion in papillary thyroid carcinoma: morphological criteria, utility of D2-40/CD31/ERG immunohistochemistry and correlation with clinicopathological characteristics.定义甲状腺乳头状癌的血管侵犯和淋巴管侵犯:形态学标准、D2-40/CD31/ERG 免疫组化的应用及与临床病理特征的相关性。
Histopathology. 2024 Dec;85(6):950-958. doi: 10.1111/his.15285. Epub 2024 Jul 18.
2
Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions.界定弥漫性硬化型乳头状甲状腺癌的基因组格局:RET融合的预后意义
Ann Surg Oncol. 2024 Sep;31(9):5525-5536. doi: 10.1245/s10434-024-15500-9. Epub 2024 Jun 7.
3
A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.
弥漫硬化型甲状腺乳头状癌的详细组织学和分子评估。
Mod Pathol. 2023 Dec;36(12):100329. doi: 10.1016/j.modpat.2023.100329. Epub 2023 Sep 15.
4
Clinicopathological and Genetic Characteristics of Patients of Different Ages with Diffuse Sclerosing Variant Papillary Thyroid Carcinoma.不同年龄弥漫性硬化型乳头状甲状腺癌患者的临床病理及遗传学特征
Cancers (Basel). 2023 Jun 7;15(12):3101. doi: 10.3390/cancers15123101.
5
Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer.弥漫硬化性乳头状甲状腺癌:与经典型和高细胞型甲状腺乳头状癌的临床病理特征和预后意义比较。
Ann Surg Oncol. 2023 Aug;30(8):4761-4770. doi: 10.1245/s10434-023-13589-y. Epub 2023 May 8.
6
Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer.弥漫性硬化性甲状腺乳头状癌的分子遗传学。
J Clin Endocrinol Metab. 2023 Aug 18;108(9):e704-e711. doi: 10.1210/clinem/dgad185.
7
Advances in Thyroid Pathology: High Grade Follicular Cell-derived Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.甲状腺病理学进展:高级滤泡细胞衍生型甲状腺癌和间变性甲状腺癌。
Adv Anat Pathol. 2023 Jan 1;30(1):3-10. doi: 10.1097/PAP.0000000000000380. Epub 2022 Oct 24.
8
Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients.儿童滤泡细胞源性甲状腺癌的临床病理和预后特征:222 例患者的回顾性研究。
Am J Surg Pathol. 2022 Dec 1;46(12):1659-1669. doi: 10.1097/PAS.0000000000001958. Epub 2022 Aug 29.
9
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
10
Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.原发性高级别非典型甲状腺癌:364 例回顾性研究。
Histopathology. 2022 Jan;80(2):322-337. doi: 10.1111/his.14550. Epub 2021 Oct 7.